 Connection
Frank Scott to Quality-Adjusted Life Years
This is a "connection" page, showing publications Frank Scott has written about Quality-Adjusted Life Years.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.646 |
|
|
|
-
Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2020 Jun 19; 14(5):575-587.
Score: 0.174
-
Johnson FR, Scott FI, Reed SD, Lewis JD, Bewtra M. Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations. Value Health. 2019 06; 22(6):684-692.
Score: 0.161
-
Scott FI, Shah Y, Lasch K, Luo M, Lewis JD. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. Inflamm Bowel Dis. 2018 01 18; 24(2):286-295.
Score: 0.147
-
Scott FI, Vajravelu RK, Bewtra M, Mamtani R, Lee D, Goldberg DS, Lewis JD. The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model. Clin Gastroenterol Hepatol. 2015 Feb; 13(2):302-309.e11.
Score: 0.116
-
Wang L, Scott FI, Boursi B, Reiss KA, Williams S, Glick H, Yang YX. Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes. Clin Gastroenterol Hepatol. 2022 09; 20(9):1997-2004.e7.
Score: 0.048
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|